{"id":"W3113331633","doi":"10.1016/j.annonc.2020.10.552","title":"64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Toray Industries; Astellas Pharma; Castle Biosciences; Moderna; Sanofi; Exelixis; Incyte; Taiho Pharmaceutical; Sun Pharma; Regeneron Pharmaceuticals; Plexxikon; Ipsen; BeiGene; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Regimen; Internal medicine; Refractory (planetary science); Melanoma; Phases of clinical research; Gastroenterology; Metastatic melanoma; Immunotherapy; Nuclear medicine; Oncology; Urology; Surgery; Cancer; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009758255,0.001125066,0.001187982,0.0004635802,0.0004485913,0.0008237236,0.0005579883,0.001016424,0.004492573],"category_scores_gemma":[0.0006890847,0.0005329789,0.00124749,0.0003733864,0.0006781206,0.0006557245,0.0003436797,0.002632826,0.000999835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007031313,"about_ca_system_score_gemma":0.001261557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00116952,"about_ca_topic_score_gemma":0.002768341,"domain_scores_codex":[0.9996647,0.0001504644,0.00001323123,0.00005809937,0.00002785523,0.00008561109],"domain_scores_gemma":[0.9995136,0.0000602734,0.00007799437,0.00005227662,0.00002775649,0.0002680766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7520017,0.05746803,0.0135781,0.0004830995,0.001254539,0.0002911536,0.0002351468,0.002163924,0.07696918,0.0002757105,0.003548894,0.09173068],"study_design_scores_gemma":[0.5124196,0.4569322,0.02061297,0.00002722044,0.0005212045,0.0002234371,0.00005003107,0.0007854506,0.005466608,0.0001966221,0.002735497,0.000029092],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951354,0.0006414732,0.0003177325,0.0002718809,0.00006592903,0.001395678,0.0008955243,0.00006116868,0.00121525],"genre_scores_gemma":[0.9875688,0.0009566454,0.00137636,0.0009304985,0.0001810994,0.001938553,0.002616238,0.00003298181,0.004398908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004492573,"threshold_uncertainty_score":0.01502919,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06684182245453124,"score_gpt":0.3730594717083754,"score_spread":0.3062176492538441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}